Progyny, INC Form 4 insider transactions

Progyny's CFO, Mark Livingston, disposed of 2,617 shares of common stock on September 3, 2024, to cover withholding taxes upon the vesting of restricted stock units.

Allison Swartz, EVP, GC of Progyny, Inc., reports the withholding of shares for tax obligations related to vesting restricted stock units.

Michael Sturmer, President of Progyny, Inc., reports a transaction involving common stock to cover withholding taxes upon vesting of restricted stock units.

Mark Livingston, CFO of Progyny, Inc., reports a transaction involving common stock related to the vesting of restricted stock units.

Michael E. Sturmer, President of Progyny, Inc., sold 9,030 shares of common stock at $30 per share on July 16, 2024, according to a Form 4 filing with the SEC.

Progyny's CEO, Peter Anevski, reports the disposal of 7,977 shares of common stock to cover withholding taxes upon vesting of restricted stock units.

David J. Schlanger, Executive Chairman of Progyny, Inc., disposed of 2,681 shares of common stock on July 1, 2024, to cover withholding taxes upon the vesting of restricted stock units.

Director Cheryl Scott sold 1,462 shares of Progyny, Inc. (PGNY) at an average price of $28.39 on June 28, 2024, leaving her with 10,098 shares.

Mark Livingston, CFO of Progyny, Inc., reports the withholding of shares for tax obligations following the vesting of restricted stock units.

Michael E. Sturmer, President of Progyny, Inc., disposed of 448 shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

Allison Swartz, EVP, GC of Progyny, Inc., reports the withholding of 1,352 common stock shares for tax obligations on May 28, 2024, leaving her with 66,731 shares.

Michael Sturmer, President of Progyny, Inc., reports the withholding of shares for tax obligations following the vesting of restricted stock units.

Mark S. Livingston, CFO of Progyny, Inc., reports the withholding of shares for tax obligations related to vesting restricted stock units.

Director Kevin K. Gordon reports acquisition and disposal of Progyny, Inc. stock and stock options.

Director Beth C. Seidenberg reports acquisition of restricted stock units and stock options, along with adjustments to direct and indirect holdings of Progyny, Inc. stock.

Director Lloyd H. Dean acquired shares and options in Progyny, Inc. on May 23, 2024, according to a Form 4 filing with the SEC.

Director Norman Payson reports acquisition of stock options and restricted stock units, along with indirect ownership details.

Director Roger C. Holstein reports acquisition of Progyny, Inc. shares and stock options.

Director Jeffrey G. Park acquired stock options and restricted stock units (RSUs) in Progyny, Inc., according to a recent SEC Form 4 filing.

Cheryl Scott, a director of Progyny, Inc., reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Director Cohen Fred E. of Progyny, Inc. reports the acquisition of stock options and restricted stock units (RSUs) on May 23, 2024.

Michael E. Sturmer, President of Progyny, Inc., sold 4,515 shares of common stock at $31.95 per share on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Progyny CEO Peter Anevski reports the withholding of shares for tax obligations and shares acquired through the employee stock purchase plan.

David J. Schlanger, Executive Chairman of Progyny, Inc., exercised stock options and sold shares on April 1, 2024, according to a Form 4 filing with the SEC.

Progyny's President, Michael Sturmer, reports acquisition of stock options and restricted stock units, as well as the sale of common stock under a pre-arranged trading plan.

Progyny's CFO, Mark Livingston, reports acquisition and disposal of company stock and stock options, including transactions related to vesting and tax obligations.

EVP and General Counsel of Progyny, Allison Swartz, was granted stock options and restricted stock units as part of an annual merit grant.

David J. Schlanger, Executive Chairman of Progyny, Inc., sold 71,272 shares of common stock on March 27, 2024, as part of a pre-arranged Rule 10b5-1 trading plan.

David Schlanger, Executive Chairman of Progyny, Inc., exercised stock options and sold shares of common stock on March 25 and 26, 2024, according to a Form 4 filing with the SEC.

David J. Schlanger, Executive Chairman of Progyny, Inc., exercised stock options and sold shares on March 21, 2024, according to a recent SEC filing.